Trial Profile
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Bumetanide; Deuterium oxide; Glucose
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms EMPA
- 01 Feb 2024 Results assessing whether Empagliflozin caused substantial redistribution of intrarenal sodium delivery and reabsorption, providing mechanistic substrate to explain some of the benefits of this class, published in the Journal of the American Society of Nephrology
- 22 May 2020 According to a Daxor Corporation media release, Daxors BVA-100 blood volume measurement device was used to determine the primary endpoint of this study.
- 15 May 2020 Results (blood volume outcome data ) published in the Circulation Journal.